Pratap Singh PhD

Pratap Singh, Ph.D., is currently a Director of Pharmacometrics at Alexion Pharmaceuticals. He manages PK/PD, translational, and systems modelling efforts for a number of clinical and non-clinical projects. Prior to joining Alexion, Pratap spent 9 years at Pfizer where he led small and large molecule modelling efforts for rare disease, inflammation, immunology and oncology research units. At Pfizer, Pratap's population modelling efforts contributed towards the regulatory approval of Taliglucerase Alpha for Gaucher's Disease. Pratap Singh received his Ph.D. from The Johns Hopkins University in the Department of Chemical and Biomolecular Engineering where his research work contributed to the discovery of novel anti-androgens for the treatment of hormone refractory prostate cancer.